Clinical Trial Update: Genetics of Response to Canagliflozin [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial at the University of Maryland, Baltimore investigating how genetics influence response to canagliflozin in type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: ACTIVE_NOT_RECRUITING